

FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Recent Posts
- The American Health Council Appoints Dr. James Bashkin, D.Phil. to the Physician Board March 31, 2020
- The American Health Council Appoints Dr. Robert W. Letton, MD to the Physician Board March 19, 2020
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020